About the job
At Olema Oncology, we are committed to pioneering innovative therapies for breast cancer and beyond. Our flagship program, palazestrant (OP-1250), represents a groundbreaking complete estrogen receptor antagonist (CERAN) currently under development for metastatic breast cancer. This treatment holds the promise of being a game changer both as a standalone therapy and in combination with other treatments for ER+/HER2- metastatic breast cancer. Additionally, we are advancing our follow-on candidate, OP-3136, a powerful KAT6 inhibitor that has the potential to set new standards in treatment.
Our success is propelled by a culture that encourages fearless support, motivation, and constructive challenge among team members. At Olema, we believe that prioritizing our people leads to exceptional outcomes. If you are eager to contribute to an unstoppable mission, we invite you to join us in making a significant impact for our patients, your career, and beyond.
View our latest corporate presentations here.
About the Role: Director of Clinical Monitoring Oversight
As the Director of Clinical Monitoring Oversight, you will report directly to the Senior Director of Clinical Operations and will play a pivotal role in providing strategic and operational leadership for global clinical site monitoring across Olema’s clinical programs. You will ensure that all clinical monitoring activities, whether conducted by internal teams, Functional Service Providers (FSPs), or Clinical Research Organizations (CROs), are executed with utmost quality, consistency, and compliance with Good Clinical Practice (GCP) regulations.
Your responsibilities will include overseeing Olema’s Clinical Monitoring Oversight Leads, regional monitoring teams, and overall site performance. You will also develop and implement monitoring oversight strategies and standards that drive operational excellence, data integrity, and inspection readiness across all clinical trials, focusing on risk-based and data-driven methodologies.
This position is based in either our Boston, MA or San Francisco, CA office and will require approximately 15% travel.
